CD274 and non-small cell lung carcinoma: The NCT04738487 study is intended to verify the efficacy of the coformulation of pembrolizumab/vibostolimab in comparison to pembrolizumab monotherapy for PD-L1-positive metastatic NSCLC patients [26].